CVM-1118, a small molecule drug developed by TaiRx (inhibits Nodal, a TGFβ family protein) is being investigated in phase 2 trials as monotherapy in advanced neuroendocrine tumors (NCT03600233) or in combination with Nivolumab in hepatocellular carcinoma (HCC) (NCT05257590). Here, TGFB1 is linked to neuroendocrine neoplasm.